-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply - NORTHBROOK, Ill., May 20, 2019 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") today announced the call for entries for the fourth annual Astellas Oncology C 3 Prize (Changing Cancer Care), a challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones. This...

Astellas ranked 22 nd on the Best Workplaces ™ in Canada list, in addition to recognition on the 2019 lists of Best Workplaces ™ in Canada for Giving Back, Inclusion and Women MARKHAM, ON , April 29, 2019 /CNW/ - Astellas Pharma Canada, Inc. (Astellas), the Canadian subsidiary of Tokyo based Astellas Pharma, Inc., has once again been honoured as one of the Best Workplaces ™ in Canada by the Great...

MARKHAM, ON, Jan. 15, 2019 /CNW/ - Astellas Pharma Canada, Inc. is proud to announce that the Company has been named on the 2019 list of Best Workplaces™ for Inclusion. Astellas received this recognition after a thorough and independent analysis conducted by Great Place to Work®. In addition to being cited for Inclusion, Astellas was named in 2018 for the third consecutive year as a Best Workplace...

MARKHAM, ON, Jan.14, 2019 /CNW/ - Astellas Pharma Canada, Inc., today announced that Health Canada approved an expanded indication for enzalutamide, an androgen receptor inhibitor for the treatment of patients with prostate cancer, following a Priority Review by Health Canada's Therapeutic Products Directorate (TPD). With this designation, enzalutamide is now indicated to treat men with non...

Campaign supports research and awareness for prostate cancer, the most commonly diagnosed cancer among Canadian men MARKHAM, ON, Nov. 21, 2018 /CNW/ - Moustaches come in many shapes, sizes and styles - they are unique and distinctive, just like the Canadian men and their loved ones who are affected by prostate cancer. This year a social media campaign sponsored by Astellas Pharma Canada, Inc....